Anti-inflammatory Nutritional Intervention in Patients With Fibromyalgia

November 12, 2021 updated by: Universidade do Porto

Effects of an Anti-inflammatory Nutritional Intervention in Disease Assessment Parameters, Inflammatory Markers, and Quality of Life of Patients With Fibromyalgia

This is a randomized clinical trial, aimed to analyse the effects of a potentially anti-inflammatory nutritional intervention in disease assessment parameters, inflammatory markers, and quality of life of Fibromyalgia patients. Patients in the intervention group will adopt an anti-inflammatory diet and a diet with a low ingestion of fermentable oligo-, di- and monosaccharides, and polyols (FODMAPs), for a 3 months period. Group control will adopt a diet based on general recommendations for healthy eating in accordance with the World Health Organization.

Study Overview

Detailed Description

The presence of low grade intestinal inflammation has been reported in Fibromyalgia (FM) patients. Other studies associate the persistence of symptoms described in FM to possible alterations of the intestinal microbiota composition, i.e. dysbiosis, with consequent existence of Small Intestinal Bacterial Overgrowth (SIBO). A sample of 100 female patients diagnosed with FM, followed-up at Portuguese Rheumathology Institute in Lisbon, will be distributed randomly in two groups. Group 1 will adopt an anti-inflammatory diet, which is characterized by the exemption of the intake of potentially inflammatory foods, namely gluten, dairy and ultra-processed foods, over a consecutive period of 3 months. During the first month, a low FODMAPs diet will be implemented, along with the anti-inflammatory diet, followed by the reintroduction of all fruits and vegetables over a consecutive period of 2 months, for a total of 3 months of intervention. Group 2 will adopt a diet based on general recommendations for healthy eating in accordance with the World Health Organization. The Ethics Committee of the Portuguese Institute of Rheumathology approved this intervention study.

The results of this study are expected to determine whether a change in patient nutrition helps to alleviate symptoms, which would optimize medical intervention.

Study Type

Interventional

Enrollment (Actual)

46

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Lisboa, Portugal
        • Instituto Portugues de Reumatologia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Diagnosis of FM performed by the physician, according to the Rome III criteria of the American College of Rheumatology, revised in 2010;
  • Ability to read and sign the Informed Consent;
  • Stable dose therapy within 4 weeks before study start.

Exclusion Criteria:

  • Patients with pathologies that prevent the follow-up of the given dietary protocol;
  • Patients currently undergoing lactation or pregnancy;
  • Prior or current clinical history of abuse of drug or other substances;
  • Change of therapy during the intervention period;
  • Presence of other inflammatory diseases;
  • Uncontrolled medical conditions (eg. Diabetes Mellitus, decompensated heart disease, renal failure, neoplastic diseases, liver diseases).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Anti-inflammatory and low FODMAPs diet
The anti-inflammatory diet is characterized by the exclusion of potential inflammatory foods, such as gluten, dairy and processed food, for three months. During the first month, a low FODMAPs diet will be implemented, followed by the reintroduction of all fruits and vegetables over a consecutive period of 2 months. Additionally, some potentially anti-inflammatory foods will be promoted: Omega-3 through specific fish (tuna fish, salmon, sardine, horse mackerel) and nuts, antioxidant rich foods, such as fruit and vegetables, and the maintenance of glycemic index.
Exemption of the intake of potentially inflammatory foods, namely gluten, dairy and processed foods, over a consecutive period of 3 months. During the first month, a low FODMAPs diet will be implemented, along with the anti-inflammatory diet, followed by the reintroduction of all fruits and vegetables over a consecutive period of 2 months.
Active Comparator: Control
Dietary counselling based on general recommendations for healthy eating according to the World Health Organization
Healthy eating counseling according to the World Health Organization

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in pain, accessed by Visual Analogue Pain Scale
Time Frame: 1 and 3 months after baseline
Accessed by Visual Analogue Pain Scale (1 question about pain intensity over the last month, score: 0-10, with 0 = a total pain relief and 10=the greatest pain ever felt).
1 and 3 months after baseline
Change in pain, accessed by Brief Pain Inventory
Time Frame: 1 and 3 months after baseline
Accessed by Brief Pain Inventory (12 questions about pain severity and pain interference; presented with 0-10 scales, with 0=no interference and 10=interferes completely; scale range from 0 to 120 - higher range represent a worst result).
1 and 3 months after baseline
Change in quality of life accessed by Revised Fibromyalgia Impact Questionnaire
Time Frame: 1 and 3 months after baseline
Accessed by Revised Fibromyalgia Impact Questionnaire (20 questions about physical functioning (score 0-3, with 0 = optimal and 3 = worst), and about work difficulty, pain, fatigue, morning tiredness, stiffness, anxiety and depression (score 1-10, with 1 = optimal and 10 = worst; scale range from 0 to 117 - higher range represent a worst result).
1 and 3 months after baseline
Change in quality of life accessed by Short-form 36
Time Frame: 1 and 3 months after baseline
Accessed by Short-form 36 (36 questions related to the last month, distributed in 8 dimensions: physical function (Score 1-3, with 1 = very limited and 3 = not limited), physical performance, pain, general health, vitality, social function, emotional performance and mental health (score 1-5, with 1 = bad and 5-optimal); scale range from 36 to 142 - higher range represent a worst result).
1 and 3 months after baseline
Change in inflammatory parameters accessed by serum C-reactive protein measurement
Time Frame: 3 months after baseline
Measurement of serum C-reactive protein (mg/L).
3 months after baseline
Change in inflammatory parameters accessed by serum erythrocyte sedimentation rate measurement
Time Frame: 3 months after baseline
Measurement of serum erythrocyte sedimentation rate (mm/h).
3 months after baseline
Change in inflammatory parameters accessed by serum interleukin-8 measurement
Time Frame: 3 months after baseline
Measurement of serum and interleukin-8 (pg/mL).
3 months after baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in fatigue accessed by Fatigue Severity Survey
Time Frame: 1 and 3 months after baseline
Accessed by 1 questionnaire: Fatigue Severity Survey (7 questions with scale from 1 to 7, with 1 = fully disagree and 7 = fully agree; scale range from 7 to 49 - higher range represent a worst result).
1 and 3 months after baseline
Change in gastrointestinal symptoms accessed by Visual Analog Scale from a list of common gastrointestinal symptoms
Time Frame: 1 and 3 months after baseline
Accessed by questionnaire: Visual Analog Scale from a list of common gastrointestinal symptoms (10 questions about gastrointestinal discomfort over the last month, score: 0-10, with 0 = none and 10 = a big discomfort; scale range from 0 to 100 - higher range represent a worst result).
1 and 3 months after baseline
Change in quality of sleep accessed by Pittsburgh Sleep Quality Index
Time Frame: 1 and 3 months after baseline
Accessed by 1 questionnaire: Pittsburgh Sleep Quality Index (18 questions with a scale from 1 to 4, with 1=no sleep disturbance and 4=to much sleep disturbance; scale range from 18 to 72 - higher range represent a worst result).
1 and 3 months after baseline
Change in weight
Time Frame: 3 months after baseline
Measurement of weight in Kilograms.
3 months after baseline
Change in waist circumference
Time Frame: 3 months after baseline
Measurement of waist circumference in centimeters.
3 months after baseline
Change in body fat mass
Time Frame: 3 months after baseline
Measurement by bio-impedance of body fat mass in percentage.
3 months after baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ana Rita Silva, MD, Universidade do Porto

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 9, 2019

Primary Completion (Actual)

June 4, 2020

Study Completion (Actual)

June 4, 2020

Study Registration Dates

First Submitted

June 4, 2019

First Submitted That Met QC Criteria

July 2, 2019

First Posted (Actual)

July 5, 2019

Study Record Updates

Last Update Posted (Actual)

November 15, 2021

Last Update Submitted That Met QC Criteria

November 12, 2021

Last Verified

November 1, 2021

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Fibromyalgia

Clinical Trials on Anti-inflammatory and low FODMAPs diet

Subscribe